



Bi-Test™ CD14 FITC-CD13 PE

Product: Anti-human Monocyte/Macrophage and Myelomonocytic Monoclonal Antibody.

Description: CD14 is present on 70-93% of Monocyte/Macrophage cells in normal peripheral blood. Identification of human Monocyte/Macrophage cells expressing the 55 kD M.W. surface antigen. CD13 is a membrane enzyme, Aminopeptidase N. Identification of human Monocytes and Granulocytes expressing the 150 kD M.W. surface antigen. Myeloid cells in regenerating bone marrow will have an increased expression of CD13 in comparison with normal bone marrow myeloid cells.

Isotype: Mouse IgG2b kappa (FITC) and IgG1 kappa (PE).

Clone: FWKW-1 (CD14 FITC) and E735.0 (CD13 PE)

Applications: Monitoring of Monocyte/Macrophage cell subsets in peripheral blood; Characterization of subtypes of leukemia's and lymphomas; Study of AIDS virus infection; Myeloid cell function studies; Analysis of hematopoietic maturation.

Use: PBMC: Add 10 μ l of MAB/ 10^6 PBMC in 100 μ l PBS. Mix gently and incubate for 15 minutes at 2^o to 8^o C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze.

WHOLE BLOOD: Add 10 μ l of MAB/100 μ l of whole blood. Mix gently and incubate for 15 minutes at room temperature (20^oC). Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer's instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.

Storage: Antibodies are supplied in PBS, 0.08% sodium azide and 0.2% protein carrier for FITC and PE. Antibodies should be stored at 4-8^o C. Monoclonal antibodies should not be frozen. Reagents are stable for the period shown on the vial label when stored properly.

Ordering Information:	Form	Vial Size	Catalog #
	Bi-Test™	50 Test	1413S
	Bi-Test™	100 Test	1413

For research use only. Not for use in human diagnostics or therapeutics.

REFERENCES:

1. Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals unexpectedly frequent reactivity with some myelomonocytic associated antibodies. Woessner S; Florensa L; Besses C; Vila RM; Galles C; Palou L; Sabrafen JS *Leuk Res* 1992;16(5):505-10
2. Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages. Landmann R; Ludwig C; Obrist R; Obrecht JP *J Cell Biochem* 1991 Dec;47(4):317-29
3. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Solary E; Casasnovas RO; Campos L; Bene MC; Faure G; Maingon P; Falkenrodt A. *Leukemia* 1992 May;6(5):393-9
4. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Wood NC; Dickens E; Symons JA; Duff GW *Clin Immunol Immunopathol* 1992 Mar;62(3):295-300
5. Expression of CD54, CD58, CD14, and HLA-DR on macrophages and macrophage-derived accessory cells and their accessory capacity. Ocklind G; Friedrichs D; Peters JH *Immunol Lett* 1992 Feb 15;31(3):253-8
6. IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Ruppert J; Friedrichs D; Xu H; Peters JH *Immunobiology* 1991 Aug;182(5):449-64
7. Induction of CD13 expression on fresh myeloid leukemia: correlation of CD13 expression with aminopeptidase-N activity. Razak K; Newland AC *Leuk Res* 1992 Jun-Jul;16(6-7):625-30
8. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D *Br J Haematol* 1992 May;81(1):40-4
9. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A *Cancer* 1992 Jan 15;69(2):396-404
10. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T *Acta Haematol* 1992;87(1-2):88-93

For research use only. Not for use in human diagnostics or therapeutics.

Exalpa Biologicals, Inc., 2 Shaker Rd, #B101, Shirley, MA 01464
Tel: 800.395.1137 or 978.425.1370, Fax: 866.924.5100 or 978.425.1376, Web: www.exalpa.com